Clinical trials: Embryonal Tumor
Neuroblastoma, Medulloblastoma
Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer
The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup (gene expression profile) and mutations.
- Conditions
- Neuroblastoma, Medulloblastoma, Brain Tumors, Rare Tumors
- Trial name
- NCT01802567
- Testing
- Guided Therapy- Pediatric Gene Analysis Platform
- Where
- 13 sites in United States
- Volunteers
- 52 people
- Sponsor
- Giselle Sholler
Glioblastoma Multiforme
Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme
CAR T cell immunotherapy has achieved great success in CD19+ B-cell malignancies. Whether this new generation of cell-based immunotherapy can be applied to solid tumors remain to be investigated, partly due to hostile…
- Trial name
- NCT02937844
- Testing
- Anti-PD-L1 CSR T cells, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Sanbo Brain Hospital
Glioma
Clinical Study for the Safety and Therapeutic Efficacy of the AI-QMMM Designed TamavaqTM Personalised Vaccine in Patients With Newly Diagnosed Glioma.
Gliomas are a heterogeneous group of tumors arising from glial cells in the central nervous system and are associated with poor prognosis and significant morbidity.
- Trial name
- TAMAVAQTM (NCT07077616)
- Testing
- Biological: personalized vaccine Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced;
- Where
- Greece
- Volunteers
- 29 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.
Glioblastoma Multiforme
Immunohistochemical Assessment of Programmed Death ligand1 and LC3B in GBM
Glioblastoma(GBM) is the most common malignant primary brain tumor and has unfortunately bad prognosis .PDL(Programmed death lignad 1)1 is alignad for a protein receptor PD1(Programmed death 1) that upon their engagement, an…
- Trial name
- NCT04284306
- Volunteers
- 61 people
- Sponsor
- Assiut University
Glioblastoma
Key Longitudinal Associations With Risk and Glioblastoma Outcomes
The goal of this observational study is to find out what factors affect the health and risks in adults with glioblastoma (GBM), a grade 4 brain cancer.
- Trial name
- Key LARGO (NCT06625684)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Duke University
Ganglioneuroblastoma, Nodular, Neuroblastoma
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
This phase II trial studies if dinutuximab, GM-CSF, isotretinoin in combination with irinotecan, and temozolomide (chemo-immunotherapy) can be given safely to patients with high-risk neuroblastoma after Consolidation therapy…
- Trial name
- NCT04385277
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 77 sites in United States, Australia and 2 more
- Volunteers
- 41 people
- Sponsor
- Children's Oncology Group
Metastatic Melanoma
A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
To evaluate the antitumor activity of IPI-504 in patients with metastatic melanoma.
- Trial name
- NCT00627419
- Testing
- IPI-504
- Where
- 17 sites in United States
- Volunteers
- 1 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
This is a Phase 1/2, open-label, dose-exploration, combination/expansion study, which will start by evaluating the safety and tolerability of NTX-301, an oral DNMT1 inhibitor, as a monotherapy in patients with advanced solid…
- Conditions
- Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Urothelial Carcinoma, High-grade Glioma
- Trial name
- NCT04851834
- Testing
- NTX-301, Platinum-based Chemotherapy, Temozolomide
- Where
- 2 sites in Australia
- Volunteers
- 12 people
- Sponsor
- Xennials Therapeutics Australia Pty Ltd
Melanoma Stage IV
Urinary Microbiome as a Biomarker for Melanoma Diagnosis and Response Prediction to Systemic Tumour Therapy
This study looks at whether the bacteria naturally present in urine (the "urinary microbiome") can help doctors better understand melanoma, a type of skin cancer, and predict how well patients respond to treatment.
- Trial name
- NCT07635732
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Medical University of Graz
Brain and Central Nervous System Tumors
Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with autologous bone marrow transplantation or…
- Trial name
- NCT00003101
- Testing
- filgrastim, busulfan, lomustine
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Melanoma
Lapatinib in Stage IV Melanoma With ERBB4 Mutations
Background: Studies of melanoma tumor samples have shown that tumor cells from approximately 20 percent of melanoma patients contain a specific mutation of a gene involved in making a protein called ERBB4, and that changes in…
- Trial name
- NCT01264081
- Testing
- Lapatinib
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent High-grade Glioma
Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
This study is a single-arm, open-label, dose-escalation and dose-expanding Phase Ⅰb/Ⅱ clinical study to evaluate the safety, tolerability, biodistribution characteristics and preliminary efficacy of recombinant human nsIL12…
- Trial name
- NCT06763965
- Testing
- BioTTT001 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Glioblastoma, Glioma
Magnetic Resonance Spectroscopic Imaging (MRS) and Tumor Perfusion of Human Glioblastoma Treated With Concurrent Radiation Therapy and Temozolomide
The purpose of this study is to learn whether 3 tesla (3T) MRI functional imaging will map a tumor more accurately allowing a more targeted delivery of radiation.
- Trial name
- NCT00250211
- Testing
- Functional MRI imaging and tomotherapy
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- AHS Cancer Control Alberta
Glioblastoma
Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma
Glioblastomas (GBM) demonstrate in vivo genetic and histologic heterogeneity that can be non-invasively identified using imaging phenotypes that identify regionally distinct areas of tumor with genetic alterations that drive…
- Trial name
- NCT03287063
- Testing
- Tumor Biopsy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Michigan Rogel Cancer Center
Malignant Melanoma
Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma
This is an open-label, multi-center, clinical phase II study to explore the correlation of the genetic make-up of the treated tumor before start of therapy and to correlate clinical response at 8 weeks as well as metabolic…
- Trial name
- BOTTOM (NCT02410863)
- Testing
- Dabrafenib, Trametinib
- Where
- 6 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Prof. Dr. med. Dirk Schadendorf
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
Immunotherapy has become the standard of care in different advanced malignancies. Its effectiveness in the palliative setting was demonstrated by several phase III trials.
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Urothelial Carcinoma
- Trial name
- ICONIC (NCT05229614)
- Testing
- Carbon Ion Therapy, Immunotherapy (Pembrolizumab)
- Where
- 4 sites in Germany, Italy
- Volunteers
- 27 people
- Sponsor
- CNAO National Center of Oncological Hadrontherapy
Glioblastomas
Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma
In the last 20 years, only temozolomide has obtained indication for the treatment of High-grade glioma (HGG). Temozolomide during and later radiation therapy has doubled one year survival and is the standard treatment for…
- Trial name
- NCT01102595
- Testing
- Temozolomide, Bevacizumab, Standard radiation therapy
- Where
- Spain
- Volunteers
- 102 people
- Sponsor
- Grupo Español de Investigación en Neurooncología
Glioblastoma, Low Grade Glioma
Mind-Body Intervention in Glioma Couples
This trial studies how well a couple-based mind body program works in improving spiritual, psychosocial, and physical quality of life in patients with high or low grade glioma or tumors that have spread to the brain and their…
- Conditions
- Glioblastoma, Low Grade Glioma, Malignant Glioma, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT03244995
- Testing
- Mind-Body Intervention Procedure, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma Multiforme (GBM)
CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM
This study is for patients that have a type of brain cancer called glioblastoma multiforme (GBM). The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers.
- Trial name
- HERT-GBM (NCT01109095)
- Testing
- HER.CAR CMV-specific CTLs
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Baylor College of Medicine
Glioma, Medulloblastoma
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Background: About 90,000 new cases of brain and spinal cord tumors are diagnosed annually in the United States. Most of these tumors are benign; however, about 30% are malignant, and 35% of people with malignant tumors in the…
- Conditions
- Glioma, Medulloblastoma, Ependymoma, Glioblastoma
- Trial name
- NCT06161519
- Testing
- PLX038
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- National Cancer Institute (NCI)